Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

NCT04605185 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma

Interventions

DRUG: Donafenib Tosilate Tablets
BIOLOGICAL: Toripalimab Injection

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd